XML 88 R74.htm IDEA: XBRL DOCUMENT v3.22.4

Collaborations and Other Arrangements (Details) € in Millions, shares in Millions								1 Months Ended							3 Months Ended		12 Months Ended
	Dec. 21, 2021 USD ($)	Mar. 13, 2021 USD ($)	Aug. 25, 2020 USD ($)	Aug. 17, 2020 USD ($) program	Jul. 13, 2020 USD ($) shares	May 29, 2020 USD ($) shares	May 27, 2020	Dec. 31, 2022 USD ($)	Apr. 30, 2022 USD ($)	Jan. 31, 2021 USD ($)	Jan. 31, 2021 EUR (€)	Oct. 31, 2020 USD ($)	Aug. 31, 2019 USD ($) shares	Dec. 31, 2018 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2021 USD ($) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Dec. 31, 2014	Dec. 31, 2022 EUR (€)	Nov. 18, 2021 program	Apr. 30, 2021 USD ($)	Apr. 30, 2021 EUR (€)	Feb. 08, 2021	Dec. 15, 2020 USD ($)	Dec. 15, 2020 EUR (€)	Oct. 23, 2020 USD ($)	Jul. 17, 2020	Jun. 19, 2020	Dec. 31, 2019 shares
Collaborative Arrangements
Acquired in-process research and development expenses																	$ 944,000,000	$ 939,000,000	$ 5,968,000,000
Research and development expenses																	4,977,000,000	4,601,000,000	4,927,000,000
Cost of goods sold																	5,657,000,000	6,601,000,000	4,572,000,000
Selling, general and administrative expenses																	5,673,000,000	5,246,000,000	5,151,000,000
Immunomedics, Inc. | Licensing Agreements
Collaborative Arrangements
Finite-lived intangible asset																												$ 175,000,000
Merck Sharp & Dohme Corp
Collaborative Arrangements
Percent of global and development and commercialization costs		60.00%
Revenues recognized																	0	0
Option period to license certain inhibitors		5 years
Merck Sharp & Dohme Corp | Merck
Collaborative Arrangements
Percent of global and development and commercialization costs		40.00%
Merck Sharp & Dohme Corp | Oral Formulation Product
Collaborative Arrangements
Net product sales threshold		$ 2,000,000,000
Percent of global product revenues		65.00%
Merck Sharp & Dohme Corp | Injectable Formulation Product
Collaborative Arrangements
Net product sales threshold		$ 3,500,000,000
Percent of global product revenues		65.00%
Arcus stock purchase agreement | Arcus
Collaborative Arrangements
Ownership percentage by noncontrolling owners																									19.50%
Janssen pharmaceuticals
Collaborative Arrangements
Purchase price of goods less specified amount, maximum percentage																				30.00%
Cost of goods sold																	483,000,000	530,000,000	570,000,000
Period subject to termination																				10 years
Japan tobacco
Collaborative Arrangements
Royalty expense																	198,000,000	250,000,000	291,000,000
Cash paid														$ 559,000,000
Finite-lived intangible assets acquired														$ 550,000,000
Amortization useful life														9 years
Everest Medicines | Licensing Agreements
Collaborative Arrangements
Finite-lived intangible assets acquired															$ 50,000,000
Finite-lived intangible asset																												$ 175,000,000
Selling, general and administrative expenses															406,000,000
Other collaboration arrangements
Collaborative Arrangements
Upfront collaboration expenses																	86,000,000	177,000,000	129,000,000
Arcus
Collaborative Arrangements
Payments to acquire shares						$ 61,000,000
Shares of common stock acquired (in shares) | shares						2.2
Arcus | Arcus collaboration agreement and stock purchase agreements
Collaborative Arrangements
Payments to acquire in process research and development					$ 175,000,000
Additional shares acquired (in shares) | shares					6.0
Payments to acquire shares					$ 200,000,000
Total upfront payments made					391,000,000
Equity investment					135,000,000
Acquired in-process research and development expenses					256,000,000													$ 625,000,000
Issuance discount (premium)					(65,000,000)
Direct transactional costs					$ 16,000,000
Opt-in term							10 years
Number of clinical stage programs with exercise options | program																						3
Collaboration opt-in payments	$ 725,000,000
Arcus | Arcus stock purchase agreement
Collaborative Arrangements
Payments to acquire shares																$ 220,000,000
Maximum percentage of outstanding stock allowed to be purchased					35.00%
Purchase period					5 years
Restriction period					3 years
Additional shares acquired (in shares) | shares																5.7
Number of shares (in shares) | shares																		13.8
Arcus | Arcus collaboration agreement
Collaborative Arrangements
Additional option fee on fourth, sixth, and eighth anniversaries					$ 100,000,000
Research and development expenses																	187,000,000
Pionyr
Collaborative Arrangements
Ownership percentage																														49.90%
Pionyr | Pionyr merger and option agreements
Collaborative Arrangements
Maximum potential future milestone payments					1,200,000,000
Acquired in-process research and development expenses																			215,000,000
Payments to acquire equity method investments					269,000,000
Equity investments balance								$ 0							0		0	$ 0
Estimated fair value					70,000,000
Option exercise fee					315,000,000
Pionyr | Research and development service agreement
Collaborative Arrangements
Acquired in-process research and development expenses																			80,000,000
Research and development future maximum payments					$ 115,000,000
Additional acquired in-process research and development expenses																			70,000,000
Tizona
Collaborative Arrangements
Ownership percentage																													49.90%
Tizona | Tizona merger and option agreements
Collaborative Arrangements
Acquired in-process research and development expenses																			272,000,000
Payments to acquire equity method investments			$ 302,000,000
Equity investments balance								0							0		0	$ 0
Estimated fair value			41,000,000
Option exercise fee			100,000,000
Tizona | Tizona merger and option agreements | Maximum
Collaborative Arrangements
Option fee and potential future milestone payments			$ 1,200,000,000
Tizona | Development agreement
Collaborative Arrangements
Acquired in-process research and development expenses																			$ 115,000,000
Tango | Tango collaboration and stock purchase agreement
Collaborative Arrangements
Payments to acquire in process research and development				$ 125,000,000
Payments to acquire shares				13,000,000
Acquired in-process research and development expenses				125,000,000
Cash payments made related to equity investments				$ 20,000,000
Number of programs | program				15
Collaboration term				7 years
Tango | Tango collaboration and stock purchase agreement | Maximum
Collaborative Arrangements
Opt-in, extension and milestone payments				$ 410,000,000
Jounce | Jounce license and stock purchase agreement
Collaborative Arrangements
Payments to acquire in process research and development								67,000,000
Total upfront payments made												$ 120,000,000
Acquired in-process research and development expenses												$ 64,000,000
Ownership percentage												14.00%
Cash payments made related to equity investments												$ 56,000,000
Galapagos | Amended 2019 agreement
Collaborative Arrangements
Potential payment for adjustments of budgeted development costs																										$ 190,000,000	€ 160
Payment for adjustments of budgeted development costs										$ 43,000,000	€ 35
Additional payment for adjustments of budgeted development costs in 2021																							$ 88,000,000	€ 75
Payment for adjustments of budgeted development costs in 2022								$ 60,000,000							60,000,000		60,000,000				€ 50
Galapagos | Galapagos subscription agreement
Collaborative Arrangements
Shares of common stock acquired (in shares) | shares													6.8																		16.7
Ownership percentage													25.80%
Maximum ownership percentage													29.90%
Standstill restricting term													10 years
Minimum ownership percentage													20.10%
Potential option exercise fee													$ 150,000,000
Payment of tiered royalties, low-end percentage													20.00%
Payment of tiered royalties, high-end percentage													24.00%
Dragonfly Therapeutics, Inc. | Dragonfly Therapeutics Collaboration Agreement
Collaborative Arrangements
Payments to acquire in process research and development									$ 300,000,000
Additional payments to acquire in process research and development																	15,000,000
Maximum potential future milestone payments																	630,000,000
Everest Medicines | Everest Medicines
Collaborative Arrangements
Maximum potential future milestone payments																	$ 175,000,000
Upfront termination payments															280,000,000
Termination payments															$ 84,000,000

X

- Definition

Additional Research And Development In Process

+ References

No definition available.

+ Details

Name:	gild_AdditionalResearchAndDevelopmentInProcess
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Adjustments of Budgeted Development Costs, Payments

+ References

No definition available.

+ Details

Name:	gild_AdjustmentsOfBudgetedDevelopmentCostsPayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Adjustments of Budgeted Development Costs, Payments, Due Next Twelve Months

+ References

No definition available.

+ Details

Name:	gild_AdjustmentsOfBudgetedDevelopmentCostsPaymentsDueNextTwelveMonths
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Cash Payments Made Related To Equity Investments

+ References

No definition available.

+ Details

Name:	gild_CashPaymentsMadeRelatedToEquityInvestments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration Arrangement, Net Product Sales Threshold

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementNetProductSalesThreshold
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Collaboration Arrangement, Percent Of Global Development And Commercialization Costs

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration Arrangement, Percent Of Global Product Revenues

+ References

No definition available.

+ Details

Name:	gild_CollaborationArrangementPercentOfGlobalProductRevenues
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Agreement, Opt-In Term

+ References

No definition available.

+ Details

Name:	gild_CollaborativeAgreementOptInTerm
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Agreement, Product Market Period Subject To Termination

+ References

No definition available.

+ Details

Name:	gild_CollaborativeAgreementProductMarketPeriodSubjectToTermination
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Arrangement, Term

+ References

No definition available.

+ Details

Name:	gild_CollaborativeArrangementTerm
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity Method Investment, Option Exercise Fee

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentOptionExerciseFee
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Equity Method Investment, Option Fee And Potential Future Milestone Payments

+ References

No definition available.

+ Details

Name:	gild_EquityMethodInvestmentOptionFeeAndPotentialFutureMilestonePayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Equity Securities, FV-NI, Additional Option Fee on Fourth, Sixth, and Eighth Anniversaries

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIAdditionalOptionFeeOnFourthSixthAndEighthAnniversaries
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity Securities, FV-NI, Option Opt-in, Extension and Milestone Payments

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIOptionOptInExtensionAndMilestonePayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Equity Securities, FV-NI, Purchase Period

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity Securities, FV-NI, Restriction Period

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIRestrictionPeriod
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Equity Securities, FV-NI, Shares

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNIShares
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Equity Securities, FV-NI, Shares Acquired

+ References

No definition available.

+ Details

Name:	gild_EquitySecuritiesFVNISharesAcquired
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Initial consideration for acquisition of rights to market and distribute certain products in Japan

+ References

No definition available.

+ Details

Name:	gild_InitialConsiderationForAcquisitionOfRightsToMarketAndDistributeCertainProductsInJapan
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Investment Owned, Balance, Additional Shares

+ References

No definition available.

+ Details

Name:	gild_InvestmentOwnedBalanceAdditionalShares
Namespace Prefix:	gild_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Issuance Discount (Premium)

+ References

No definition available.

+ Details

Name:	gild_IssuanceDiscountPremium
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Maximum Ownership Percentage In Galapagos Based On The Terms Of The Subscription Agreement

+ References

No definition available.

+ Details

Name:	gild_MaximumOwnershipPercentageInGalapagosBasedOnTheTermsOfTheSubscriptionAgreement
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Minimum Ownership Percentage in Galapagos Based on the Terms of the Subscription Agreement

+ References

No definition available.

+ Details

Name:	gild_MinimumOwnershipPercentageinGalapagosBasedontheTermsoftheSubscriptionAgreement
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number Of Clinical Stage Programs With Exercised Options

+ References

No definition available.

+ Details

Name:	gild_NumberOfClinicalStageProgramsWithExercisedOptions
Namespace Prefix:	gild_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Number of Programs

+ References

No definition available.

+ Details

Name:	gild_NumberOfPrograms
Namespace Prefix:	gild_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Payment for Adjustments of Budgeted Development Costs

+ References

No definition available.

+ Details

Name:	gild_PaymentForAdjustmentsOfBudgetedDevelopmentCosts
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Payments for Direct Transactional Expense

+ References

No definition available.

+ Details

Name:	gild_PaymentsForDirectTransactionalExpense
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Payments To Acquire Additional In Process Research And Development

+ References

No definition available.

+ Details

Name:	gild_PaymentsToAcquireAdditionalInProcessResearchAndDevelopment
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Payments To Opt-In The Collaborative Agreement

+ References

No definition available.

+ Details

Name:	gild_PaymentsToOptInTheCollaborativeAgreement
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Payments To Terminate Previous Agreement

+ References

No definition available.

+ Details

Name:	gild_PaymentsToTerminatePreviousAgreement
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Potential Future Milestone Payments, Maximum

+ References

No definition available.

+ Details

Name:	gild_PotentialFutureMilestonePaymentsMaximum
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Potential Option Exercise Fee Per Program

+ References

No definition available.

+ Details

Name:	gild_PotentialOptionExerciseFeePerProgram
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Potential Payment for Adjustments of Budgeted Development Costs

+ References

No definition available.

+ Details

Name:	gild_PotentialPaymentForAdjustmentsOfBudgetedDevelopmentCosts
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Potential Sales Based Tiered Royalties High-end, Percentage

+ References

No definition available.

+ Details

Name:	gild_PotentialSalesBasedTieredRoyaltiesHighEndPercentage
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Potential Sales Based Tiered Royalty, Low-end, Percentage

+ References

No definition available.

+ Details

Name:	gild_PotentialSalesBasedTieredRoyaltyLowEndPercentage
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Purchase Price Of Goods Less Specified Amount, Maximum Percentage

+ References

No definition available.

+ Details

Name:	gild_PurchasePriceOfGoodsLessSpecifiedAmountMaximumPercentage
Namespace Prefix:	gild_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

Research and Development Future Maximum Payments

+ References

No definition available.

+ Details

Name:	gild_ResearchAndDevelopmentFutureMaximumPayments
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Standstill Restricting Term

+ References

No definition available.

+ Details

Name:	gild_StandstillRestrictingTerm
Namespace Prefix:	gild_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Total Upfront Payments Made

+ References

No definition available.

+ Details

Name:	gild_TotalUpfrontPaymentsMade
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Up-Front Collaboration And Licensing Expenses Related To Other Collaboration Arrangements That Are Not Individually Significant

+ References

No definition available.

+ Details

Name:	gild_UpFrontCollaborationAndLicensingExpensesRelatedToOtherCollaborationArrangementsThatAreNotIndividuallySignificant
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Upfront Payments To Terminate Previous Agreement

+ References

No definition available.

+ Details

Name:	gild_UpfrontPaymentsToTerminatePreviousAgreement
Namespace Prefix:	gild_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of identifiable intangible assets recognized as of the acquisition date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599

+ Details

Name:	us-gaap_EquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Fair value portion of investments accounted under the equity method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 25
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567

+ Details

Name:	us-gaap_EquityMethodInvestmentsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740

+ Details

Name:	us-gaap_EquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

+ Details

Name:	us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Balance held at close of period in number of shares.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-12B(Column B))
-URI https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010

+ Details

Name:	us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.

+ References

No definition available.

+ Details

Name:	us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 45
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585

+ Details

Name:	us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_VariableInterestEntityLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=gild_ImmunomedicsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	dei_LegalEntityAxis=gild_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OralFormulationProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_OwnershipAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_JanssenPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AgreementWithJapanTobaccoIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_EverestMedicinesAndImmunomedicsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementAndStockPurchaseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ArcusCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_PionyrImmunotherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_PionyrMergerAndOptionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_ResearchAndDevelopmentServiceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TizonaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_TizonaMergerAndOptionAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_DevelopmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_TangoTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AmendedAndRestatedResearchCollaborationAndLicenseAgreementAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_JounceTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_LicenseRegistrationRightsAndStockPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_GalapagosMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_AmendedFilgotinibLicenseAndCollaborationAgreementInDecember2020Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_GalapagosSubscriptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=gild_DragonflyTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=gild_DragonflyTherapeuticsCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=gild_EverestMedicinesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: